MGMerab M. Gabrava

Merab M. Gabrava

*This is an algorithmically generated author record based on publicly available information.

Merab M. Gabrava has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Surgical treatment of pheochromocytoma complicated by tumor thrombosis of the inferior vena cava: a post-hoc analysis and series of clinical cases

    by Maryam R. Tamrazova, Тамразова Марьям Романовна, Vagan Yu. Bokhian, Бохян Ваган Юрикович, Merab M. Gabrava, Габрава Мераб Мерабович, Yaroslav A. Zhulikov, Жуликов Ярослав Андреевич, Kazbek A. Batyrov, Батыров Казбек Ахмедович, et al.

    Aim. To describe the surgical approach and evaluate the results of treatment in a series of cases of pheochromocytoma complicated by tumor thrombosis of the inferior vena cava (IVC). Materials and methods. The study presents the experience with surgical treatment of patients with pheochromocytoma complicated by IVC tumor thrombosis. From 1989 to 2024, 181 patients with pheochromocytoma underwent surgical treatment at the Blokhin National Medical Research Center of Oncology, of whom 7 (3.9%) had an IVC involvement. In 6 cases, the patients were males aged 17 to 73 years, and in 1 case, a female aged 66 years. In all cases, tumor thrombosis of the IVC was due to right-sided pheochromocytoma, including in 1 patient with bilateral adrenal gland involvement. Pheochromocytoma was diagnosed based on clinical, laboratory, and imaging data (CT scan, combined positron-emission and CT scan, and magnetic resonance imaging) and confirmed by histological and immunohistochemical studies. Surgical approach included radical removal of the tumor with thrombectomy from the IVC in 4 patients. In 2 cases, exploratory interventions were performed, and 1 patient received drug treatment. Particular attention is paid to the surgical procedure, which requires careful planning and an individual approach to each patient. The surgery includes the technique of removing blood clots with their full visualization due to the structure of tumor thrombi and the risk of fragmentation and embolism. Results. No postoperative mortality was reported. During follow-up (up to 5 years), no recurrence or progression was detected in the patients. Conclusion. Tumor thrombosis of the IVC in pheochromocytoma is uncommon. Surgery is the treatment of choice, providing radical tumor removal and achieving long-term remission in pheochromocytoma. Particular attention should be paid to the characteristics of the tumor thrombi, which, according to our observations, have a loose consistency and often a tight attachment to the vascular wall, increasing the risk of fragmentation. Therefore, thrombectomy should be performed with careful visualization and control of all thrombotic masses to minimize intraoperative embolism.

  • Pheochromocytomas and paragangliomas in patients with congenital heart defects

    by V. Y. Bokhian, T. Y. Danilov, M. R. Tamrazova, M. M. Gabrava, Y. A. Zhulikov, A. R. Shin, A. M. Mikhaylova

    The correlation between pheochromocytoma/paraganglioma (PHEO/PGL) and cyanotic congenital heart defects is rare but not coincidental. Research suggests that the development of PHEO/PGL in these patients maybe explained by chronic hypoxia, disruptions in the sympathetic nervous system, and potential genetic predisposition. These factors may provoke the tumor transformation of chromaffin cells. Additionally, diagnosing PHEO/PGL in patients with heart defects is complicated by hemodynamic disturbances that mask the characteristic sympathoadrenal crises of PHEO/PGL. The occurrence of these neoplasms can exacerbate the clinical course of congenital defects due to increased catecholamine secretion, leading to vasoconstriction and worsening hypoxia. We present two clinical cases of PHEO/PGL in the context of congenital heart defects, with patients observed and treated at the N.N. Blokhin National Medical Research Center of Oncology and the A.N. Bakoulev National Medical Research Center of Cardiovascular Surgery. These observations emphasize the importance of vigilance for symptoms of tachycardia and uncontrolled hypertension in such patients. Despite their rarity, the relationship between these pathologies must be considered for accurate diagnosis and optimal treatment selection.

  • Retrospective Analysis of the Effectiveness of Somatostatin Analogs in the Treatment of Metastatic Pheochromocytoma/Paraganglioma. A Clinical Case on the efficacy of long-acting release octreotide

    by Y. A. Zhulikov, E. I. Kovalenko, K. N. Galanova, A. N. Tyatyushkina, E. V. Evdokimova, A. A. Markovich, V. Yu. Bokhyan, M. M. Gabrava, O. A. Martynova, V. V. Delektorskaya, et al.

    Introduction. Pheochromocytoma (PC) and paraganglioma (PG) are neuroendocrine neoplasms and are characterized by a high frequency of somatostatin receptor (SSTR) expression. The efficacy of somatostatin analogues in PC/PG remains poorly studied, despite the lack of evidence base, these drugs are included in the international NCCN recommendations. The aim of this study was to investigate the effectiveness of somatostatin analogues in the treatment of PC/PG.Materials and methods. This retrospective single-center study included patients older than 18 years with positive expression of SSTR 2A и/или SSTR 5 or with accumulation of 68Ga-DOTATATE who received somatostatin analogs (octreotide-depo or lanreotide) at the first line of treatment for metastatic PC/PG from April 2020 to September 2023.Results. The study included 8 patients, 6 male (75 %) and 2 female (25 %). All patients had positive SSTR 2A expression and accumulation on 68Ga-DOTATATE PET. Half patients (N=4, 50 %) had pheochromocytoma and half (N=4, 50 %) paraganglioma. SDHB mutation was detected in 1 (12.5 %) patient. Four patients (50 %) had disease progression on follow-up before starting therapy with somatostatin analogues. No objective response was achieved (0 %). However, all patients had disease control ≥ 6 months. Two (33.3 %) of 6 had a ≥ 50 % decrease in metanephrine/ normetanephrine secretion. Median PFS was 21.57 months. (95 % Confidence Interval 14.95–28.19).Conclusion. Based on our findings, we recommend considering somatostatin analogs as a first-line treatment option for patients with indolent disease course and low tumor burden who demonstrate progression during active surveillance. The impact of long-acting somatostatin analogs on catecholamine secretion warrants further investigation in a prospective cohort.

  • Open Access

    Features of regional relapses in the central zone after surgical treatment of highly differentiated thyroid cancer

    by E. Kh. Gogieva, I. S. Romanov, V. Yu. Bokhyan, A. V. Ignatova, M. M. Gabrava, A. K. Zarenkova, A. B. Safonova, K. A. Batyrov, В. Ю. Бохян

    Introduction. Thyroid cancer is the most common malignant tumor of the endocrine system and comprises 33 % of malignant neoplasms of the head and neck. first echelon lymph nodes affected by this pathology are located in the central area of the neck. The metastatic process further advances into the lymph nodes in the lateral tissues of the neck. Currently, there is no consensus on the effectiveness of prophylactic central lymph node dissection and no conclusive criteria determining the risk of recurrence in the central zone.Aim. The assessment of factors influencing the risk of regional recurrence in the central zone.Materials and methods. The study included 30 patients with highly differentiated thyroid cancer, in whom metastatic nodes in the central zone were identified and verified during primary treatment. All patients previously underwent unilateral or 2-sided central lymph node dissection in various institutions. During the period of dynamic observation, these patients revealed regional recurrence in the central zone. patients were observed and treated for recurrence at the National medical Research Center of Oncology named after N.N. Blokhin of the ministry of Health of Russia.Results. primary surgical treatment in a specialized oncological institution was performed in 21 (70 %) patients, in a general surgical medical institution – in 7 (23.3 %), in an endocrinological institution – in 2 (6.7 %) patients. when assessing the influence of the morphological type and variant of thyroid cancer on the risk of developing regional recurrence, no statistical significance was found. No statistically significant factors were found in the analysis of the influence of characteristics of the primary tumor, such as tumor size, multifocal lesion, vascular invasion, extrathyroidal spread, on the risk of regional recurrence. In 16 (53.3 %) patients, recurrence occurred in the paratracheal zone of the ipsilateral side, in 7 (23.3 %) patients in the paratracheal zone of the contralateral side, bilateral lesions were observed in 2 (6.67 %) cases. 3 (10 %) patients were diagnosed with transient parathyroid insufficiency, 1 (3.3 %) – permanent parathyroid insufficiency, 1 (3.3 %) – hematoma in the area of the postoperative wound, patient, 2 (6.6 %) – injury to the recurrent laryngeal nerve.Conclusion. Residual metastatic lymph nodes after previous surgical treatment are the reason for performing a second operation, which carries both the risks of postoperative complications and the psychological burden on the patient. Thus, an adequate and radically performed primary surgical intervention is the key to reducing regional recurrences.

  • Open Access

    Pancreatic leiomyosarcoma: a case report

    by M. P. Nikulin, V. V. Yugay, N. A. Kozlov, P. P. Arkhiri, M. M. Gabrava, S. S. Magamedova, I. S. Stilidi

    Primary pancreatic leiomyosarcoma belongs to a rare group of malignant soft tissue tumors. we present a clinical case of a 61-year-old patient who underwent hemipancreatectomy with splenectomy for a pancreatic tumor in 2018. Histological and immunohistochemical studies confirmed the diagnosis of leiomyosarcoma. for three years, the patient has been observed at the N.N. Blokhin National Medical Research Center of Oncology of ministry of Health of Russia without signs of progression.